Expert: Fully human IgG2 monoclonal antibody targeting RANK ligand (RANKL). Inhibits osteoclast formation, function, and survival, reducing bone resorption.

Everyday: Blocks a signal (RANKL) that tells bone-eating cells to break down bone. Without this signal, your bones stay stronger and denser — like telling the demolition crew to stop working.

Targets: ["RANKL"]

BIOSIMILAR RISK: 8+ denosumab biosimilars approved. Analysts expect 28% decline in 2026. SC biologic may erode slower than IV (compliance advantage with Q6M dosing).